Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma
Status:
Terminated
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Phase I/II trial to estimate the maximum tolerated dose of imatinib mesylate in newly
diagnosed brain stem gliomas and recurrent high grade gliomas and to assess the effectiveness
of imatinib mesylate in treating young patients who have newly diagnosed intrinsic brain stem
glioma. Imatinib mesylate may interfere with the growth of tumor cells by blocking the
enzymes necessary for their growth. Radiation therapy uses high-energy x-rays to damage tumor
cells. Combining imatinib mesylate with radiation therapy may kill more tumor cells.